A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

References

• Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47; PMID:16291983; http://dx.doi.org/10.1056/NEJMoa050092
   PubMed Web of Science ®Google Scholar
• Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma. Curr Opin Oncol 2015; 27:141-50; PMID:25588041; http://dx.doi.org/10.1097/CCO.0000000000000159
   PubMed Web of Science ®Google Scholar
• Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res: Off Am Assoc Cancer Res 2013; 19:5320-8; PMID:24089445; http://dx.doi.org/10.1158/1078-0432.CCR-13-0259
   PubMed Web of Science ®Google Scholar
• Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 1998; 22:157-63; PMID:9598804; http://dx.doi.org/10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014; 27:590-600; PMID:24495407; http://dx.doi.org/10.1111/pcmr.12228
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-31; PMID:11902577; http://dx.doi.org/10.1038/35106065
   PubMed Web of Science ®Google Scholar
• Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell Melanoma Res 2014; 27:351-65; PMID:24405945; http://dx.doi.org/10.1111/pcmr.12211
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10.1038/nrc2602
   PubMed Web of Science ®Google Scholar
• Gupta S, Jain MM, Maru A, Nag SM, Somani N, Mehta AO, et al. Abstract: A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2012; 30(supplement):3011
   Google Scholar
• Joshi KS, Padgaonkar A, Rathos M, Wagh V, Manohar S, Bhatia D, et al. Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity. Cancer Res 2012; 72(8 Supplement):3054; PMID:22282653; http://dx.doi.org/10.1158/1538-7445.AM2012-3054
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630-41; PMID:16236519; http://dx.doi.org/10.1016/j.tibs.2005.09.005
   PubMed Web of Science ®Google Scholar
• Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PloS One 2013; 8:e59588; PMID:23527225; http://dx.doi.org/10.1371/journal.pone.0059588
   PubMed Web of Science ®Google Scholar
• Fisher RP. The CDK network: linking ycles of cell division and gene expression. Genes Cancer 2012; 3:731-8; PMID:23634260; http://dx.doi.org/10.1177/1947601912473308
   PubMedGoogle Scholar
• Rudy W, Guckel B, Siebels M, Lindauer M, Meuer SC, Moebius U. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. Int Immunol 1997; 9:853-60; PMID:9199968; http://dx.doi.org/10.1093/intimm/9.6.853
   PubMed Web of Science ®Google Scholar
• Katagata Y, Aoki T, Hozumi Y, Yoshida T, Kondo S. Identification of K1/K10 and K5/K14 keratin pairs in human melanoma cell lines. J Dermatol Sci 1996; 13:219-27; PMID:9023704; http://dx.doi.org/10.1016/S0923-1811(96)00538-5
   PubMed Web of Science ®Google Scholar
• Saito Y, Wang Z, Hagino-Yamagishi K, Civelli O, Kawashima S, Maruyama K. Endogenous melanin-concentrating hormone receptor SLC-1 in human melanoma SK-MEL-37 cells. Biochem Biophys Res Commun 2001; 289:44-50; PMID:11708774; http://dx.doi.org/10.1006/bbrc.2001.5926
   PubMed Web of Science ®Google Scholar
• van Ham SM, Tjin EP, Lillemeier BF, Gruneberg U, van Meijgaarden KE, Pastoors L, Verwoerd D, Tulp A, Canas B, Rahman D, et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol 1997; 7:950-7; PMID:9382849; http://dx.doi.org/10.1016/S0960-9822(06)00414-3
   PubMed Web of Science ®Google Scholar
• Padua RA, Barrass NC, Currie GA. Activation of N-ras in a human melanoma cell line. Mol Cell Biol 1985; 5:582-5; PMID:3887133; http://dx.doi.org/10.1128/MCB.5.3.582
   PubMed Web of Science ®Google Scholar
• Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcala A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 2013; 19:4383-91; PMID:23812671; http://dx.doi.org/10.1158/1078-0432.CCR-13-0074
   PubMed Web of Science ®Google Scholar
• Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 2012; 132:356-64; PMID:21993556; http://dx.doi.org/10.1038/jid.2011.313
   PubMed Web of Science ®Google Scholar
• Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, Jonsson G, Frederick DT, Tsao H. BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 2015; 135:1089-97; PMID:25521456; http://dx.doi.org/10.1038/jid.2014.528
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10
   PubMed Web of Science ®Google Scholar
• Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 2011; 10:977-88; PMID:21358262; http://dx.doi.org/10.4161/cc.10.6.15079
   PubMed Web of Science ®Google Scholar
• Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer ther 2014; 13:2253-63; PMID:25122067; http://dx.doi.org/10.1158/1535-7163.MCT-14-0257
   PubMed Web of Science ®Google Scholar
• Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Res 2013; 19:4868-78; PMID:23833299; http://dx.doi.org/10.1158/1078-0432.CCR-13-0827
   PubMed Web of Science ®Google Scholar